Last reviewed · How we verify

NCT03409952

Lutronic LaseMD for Treatment of Benign Pigmented Lesions

Completed NA Last updated 13 March 2019
What this trial tests

NA trial testing LaseMD and DUAL 1927nm Laser in Benign Pigmented Lesions in 20 participants. Completed in 25 February 2019.

Timeline
17 November 2017
Primary endpoint
20 December 2018
25 February 2019

Quick facts

Lead sponsorCynosureLutronic
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationnon randomized
Designsequential
Maskingsingle
Primary purposetreatment
Enrollment20
Start date17 November 2017
Primary completion20 December 2018
Estimated completion25 February 2019
Sites2 locations across United States

Drugs / interventions tested

Conditions studied

Sponsor

CynosureLutronic — full company profile →

Who can join

18 and older, any sex, with Benign Pigmented Lesions. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The Lutronic LaseMD Laser System will be evaluated for the treatment of benign pigmented lesions.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Benign Pigmented Lesions

Currently open trials in the same condition.

Other CynosureLutronic trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03409952.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing